Clinical trial Recruiting at 2 sites Interventional Ages 14 Days to 28 Days

Growth, tolerance, and gut markers in healthy infants given dietary supplements

Official title: Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements: A Double-blind, Randomized Placebo-controlled Nutritional Study

Run by Société des Produits Nestlé (SPN) · NCT07630584 · Data updated 2026-11-12

This study tests whether giving probiotic supplements to healthy newborns helps with weight gain and gut health compared with a placebo.

More Healthy Infants trials

Quick facts

Study typeInterventional
Ages14 Days to 28 Days
SexAll
Enrollment327 (estimated)
SponsorSociété des Produits Nestlé (SPN)
Industry-sponsored
Locations2 sites (Cavite City, Manila and 1 other locations)
StatusRecruiting
StartedAugust 11, 2026
Main results expectedJuly 31, 2027
Study endsDecember 31, 2027
Registry record updatedSeptember 14, 2026
Trial IDNCT07630584 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy term infants aged 14 to 28 days at enrollment whose parents consent and agree to follow study requirements.

Probably not a fit

Infants who do not respond to probiotics or who have underlying conditions not included in the study are less likely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a double-blind, randomized, placebo-controlled study in healthy term infants from birth to 2.5 months old. Approximately 327 infants between 14 and 28 days old are enrolled and followed for about 3 months, with 8 weeks of intervention and 4 weeks of follow-up. Infants receive either a single probiotic, a multi-probiotic, or a placebo, and outcomes include weight gain, growth patterns, gastrointestinal tolerance, fecal microbiome and metabolic markers, and safety. The primary goal is non-inferior weight gain during the first 8 weeks; secondary aims cover gut health biomarkers and safety through the end of follow-up.

Why it matters

Potential benefit: If successful, the probiotic supplements could support healthy growth and gut health in early infancy.

How similar studies have gone: Prior probiotic studies in infants have shown mixed but promising signals for gut health and growth, making this approach plausible but not yet proven for non-inferiority in weight gain.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Written informed consent has been obtained from at least one parent (or legally acceptable representative \[LAR\])
2. Parent(s) / LAR(s) must be able to provide evidence of parental authority and identity
3. Parent(s) / LAR(s) must understand the informed consent form and other study documents
4. Parent(s) / LAR(s) are willing and able to comply with scheduled visits and the requirements of the study protocol
5. Parent(s) / LAR(s) can be contacted directly by telephone throughout the study
6. Parent(s) / LAR(s) must be able to temporarily store stool samples in a household freezer
7. Infants may be exclusively breastfed, exclusively formula-fed, or mixed fed with both breast milk and infant formula in any proportion. Parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding until the end of the study period:

   1. For exclusively breastfed infants: parents must intend to continue exclusive breastfeeding. As defined by the World Health Organization, exclusive breastfeeding means that the infant receives only breast milk. No other liquids or solids are given (not even water) with the exception of oral rehydration solution, or drops/syrups of vitamins, minerals, or medicines.
   2. For formula-fed infants (either exclusively or mixed-fed): parent(s) / LAR(s) must intend to maintain the infant's current mode of feeding, plus:

      * Parents / LAR(s) must have previously and independently decided to use formula
      * Infant must be consuming and tolerating a standard cow's milk infant formula not containing probiotics at the time of enrollment
8. Infant must be healthy based on medical history and physical examination
9. Infant full-term gestational birth (born 37 weeks, 0 days through 41 weeks, 6 days of gestation)
10. Infant singleton birth
11. Infant postnatal age ≥ 14 and ≤ 28 days (date of birth = day 0)
12. Infant birth weight is appropriate for gestational age (≥ 2500 and ≤ 4500 grams)

Exclusion Criteria:

1. Infants with conditions requiring specific infant feeding regimens other than those specified in the protocol
2. Infants who have a medical condition or medical history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:

   1. Evidence of major congenital malformations (e.g., cleft palate, extremity malformation)
   2. Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis)
   3. Previous or ongoing antibiotic usage by the infant, except when given for prophylactic reasons (e.g., erythromycin ophthalmic ointment)
   4. Immunocompromised infants and those who have a central venous catheter
   5. History of admission to the Neonatal Intensive Care Unit, except for admission for jaundice phototherapy
   6. Known or suspected allergy to milk (including lactose) or soy
   7. Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgement of the investigator, would make the infant inappropriate for entry into the study
3. Infants who are currently receiving or who have received any probiotic supplements or infant formula containing probiotics prior to enrollment
4. Infants who are currently receiving or who have received any of the following medication(s) or supplement(s) which are known or suspected to affect fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes), stool characteristics (e.g., glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose), growth (e.g. insulin or growth hormone), microbiome-related endpoints (e.g., prebiotic supplements), or gastric acid secretion
5. Infants whose parent(s) / LAR(s) have not reached the legal age of majority (18 years old)
6. Infants who are currently or who previously participated in another interventional clinical study
7. Parent(s) / LAR(s) with family or hierarchical relationships with the research team members

Where it's running

  • Health Index Multispecialty and Lying-In Clinic
    Cavite City, Manila, Philippines
    Recruiting
  • University of the East Ramon Magsaysay Memorial Medical Center, Inc.
    Quezon City, Manila, Philippines
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.